ALSO NOTED: Neurologix touts Phase I results; QLT CEO resigns; BioLineRx gains $9M in new funding; FDA to miss action date on H

> Neurologix of Fort Lee, New Jersey, reported positive interim results for its Phase I trial of its gene therapy for Parkinson's. Release

> QLT CEO Paul Hastings has resigned just days after its anti-blindness therapy failed in clinical trials. Report

> Israel's BioLineRx has lined up $9 million in funding. Release

> San Diego-based Halozyme Therapeutics says that regulators at the FDA have told the company that it cannot meet a planned action date for Hylenex. Release

> Emisphere of Tarrytown, New York, has lined up $15 million in new financing from its largest shareholder. Release

> Qiagen of The Netherlands will buy all outstanding shares of Shenzhen PG Biotech. Release

> BioNovo has moved its operations to a new facility in Emeryville, California. Release

> The Florida Sun-Sentinel looks at the recent trials and tribulations of the generic drug maker Andrx. Story

> Canada's Viron Therapeutics has begun a Phase II trial of its lead anti-inflammatory drug, VT-111. Release

And Finally… Bees kill more people in the U.S. than any other animal, and health experts believe that inadequate treatment at emergency centers may be a leading reason why. Article

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.